Literature DB >> 15801841

Druggability indices for protein targets derived from NMR-based screening data.

Philip J Hajduk1, Jeffrey R Huth, Stephen W Fesik.   

Abstract

An analysis of heteronuclear-NMR-based screening data is used to derive relationships between the ability of small molecules to bind to a protein and various parameters that describe the protein binding site. It is found that a simple model including terms for polar and apolar surface area, surface complexity, and pocket dimensions accurately predicts the experimental screening hit rates with an R(2) of 0.72, an adjusted R(2) of 0.65, and a leave-one-out Q(2) of 0.56. Application of the model to predict the druggability of protein targets not used in the training set correctly classified 94% of the proteins for which high-affinity, noncovalent, druglike leads have been reported. In addition to understanding the pocket characteristics that contribute to high-affinity binding, the relationships that have been defined allow for quantitative comparative analyses of protein binding sites for use in target assessment and validation, virtual ligand screening, and structure-based drug design.

Mesh:

Substances:

Year:  2005        PMID: 15801841     DOI: 10.1021/jm049131r

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  145 in total

1.  Targeting zinc finger domains with small molecules: solution structure and binding studies of the RanBP2-type zinc finger of RBM5.

Authors:  Biancamaria Farina; Roberto Fattorusso; Maurizio Pellecchia
Journal:  Chembiochem       Date:  2011-12-16       Impact factor: 3.164

2.  Hot spot analysis for driving the development of hits into leads in fragment-based drug discovery.

Authors:  David R Hall; Chi Ho Ngan; Brandon S Zerbe; Dima Kozakov; Sandor Vajda
Journal:  J Chem Inf Model       Date:  2011-12-15       Impact factor: 4.956

Review 3.  Evolutionary origins of the estrogen signaling system: insights from amphioxus.

Authors:  G V Callard; A M Tarrant; A Novillo; P Yacci; L Ciaccia; S Vajda; G-Y Chuang; D Kozakov; S R Greytak; S Sawyer; C Hoover; K A Cotter
Journal:  J Steroid Biochem Mol Biol       Date:  2011-04-14       Impact factor: 4.292

4.  FTSite: high accuracy detection of ligand binding sites on unbound protein structures.

Authors:  Chi-Ho Ngan; David R Hall; Brandon Zerbe; Laurie E Grove; Dima Kozakov; Sandor Vajda
Journal:  Bioinformatics       Date:  2011-11-22       Impact factor: 6.937

5.  Molecular simulation methods in drug discovery: a prospective outlook.

Authors:  Xavier Barril; F Javier Luque
Journal:  J Comput Aided Mol Des       Date:  2011-12-08       Impact factor: 3.686

6.  Domain motion and interdomain hot spots in a multidomain enzyme.

Authors:  Gwo-Yu Chuang; Ritcha Mehra-Chaudhary; Chi-Ho Ngan; Brandon S Zerbe; Dima Kozakov; Sandor Vajda; Lesa J Beamer
Journal:  Protein Sci       Date:  2010-09       Impact factor: 6.725

7.  Relationship between hot spot residues and ligand binding hot spots in protein-protein interfaces.

Authors:  Brandon S Zerbe; David R Hall; Sandor Vajda; Adrian Whitty; Dima Kozakov
Journal:  J Chem Inf Model       Date:  2012-07-24       Impact factor: 4.956

8.  Fragment-based identification of druggable 'hot spots' of proteins using Fourier domain correlation techniques.

Authors:  Ryan Brenke; Dima Kozakov; Gwo-Yu Chuang; Dmitri Beglov; David Hall; Melissa R Landon; Carla Mattos; Sandor Vajda
Journal:  Bioinformatics       Date:  2009-01-28       Impact factor: 6.937

Review 9.  Perspectives on NMR in drug discovery: a technique comes of age.

Authors:  Maurizio Pellecchia; Ivano Bertini; David Cowburn; Claudio Dalvit; Ernest Giralt; Wolfgang Jahnke; Thomas L James; Steve W Homans; Horst Kessler; Claudio Luchinat; Bernd Meyer; Hartmut Oschkinat; Jeff Peng; Harald Schwalbe; Gregg Siegal
Journal:  Nat Rev Drug Discov       Date:  2008-09       Impact factor: 84.694

Review 10.  Expanding the number of 'druggable' targets: non-enzymes and protein-protein interactions.

Authors:  Leah N Makley; Jason E Gestwicki
Journal:  Chem Biol Drug Des       Date:  2013-01       Impact factor: 2.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.